Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. - Archive ouverte HAL Access content directly
Journal Articles Journal of Neurology, Neurosurgery and Psychiatry Year : 2009

Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.

(1, 2) , (2) , (3) , (2, 4) , (5) , (1, 2) , (6) , (1) , (6) , (7) , (8) , (2, 4)
1
2
3
4
5
6
7
8

Abstract

OBJECTIVE: Anti-Hu antibodies (Hu-Ab) and anti-CV2/CRMP5 antibodies (CV2/CRMP5-Ab) have been identified in association with paraneoplastic neurological disorders. However, it is not clear whether these antibodies are associated with specific neurological symptoms or are only markers of anti-cancer immune reaction. METHODS: To address this question, 37 patients with CV2/CRMP5-Ab and 324 patients with Hu-Ab were compared. RESULTS: Whereas the age and sex ratio were the same between the two groups, the distribution of neurological symptoms was not. Patients with CV2/CRMP5-Ab presented more frequently cerebellar ataxia, chorea, uveo/retinal symptoms and myasthenic syndrome (Lambert-Eaton myasthenic syndrome LEMS or myasthenia gravis). They also had a better Rankin score. In contrast, dysautonomia, brainstem encephalitis and peripheral neuropathy were more frequent in patients with Hu-Ab. Limbic encephalitis occurred similarly in both groups. Small-cell lung cancer was the most frequently associated tumour in both groups of patients, while malignant thymoma was observed only in patients with CV2/CRMP5-Ab. In particular, patients with CV2/CRMP5-Ab and thymoma developed myasthenic syndrome more frequently, while patients with SCLC developed neuropathies more frequently. Chorea and myasthenic syndrome were only seen in patients with CV2/CRMP5-Ab. The median survival time was significantly longer in patients with CV2/CRMP5-Ab, and this effect was not dependent on the type of tumour. Interpretation: The data demonstrate that in patients with paraneoplastic neurological syndromes, the neurological symptoms and survival vary with both the type of associated onco-neural antibody and the type of tumour.
Fichier principal
Vignette du fichier
Honnorat_et_al_.pdf (374.66 Ko) Télécharger le fichier
Vignette du fichier
inserm-00321230_edited.pdf (211.43 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)

Dates and versions

inserm-00321230 , version 1 (23-10-2008)

Identifiers

Cite

Jérôme Honnorat, Stéphanie Cartalat-Carel, Damien Ricard, Jean-Philippe Camdessanche, Antoine F. Carpentier, et al.. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80 (4), pp.412-6. ⟨10.1136/jnnp.2007.138016⟩. ⟨inserm-00321230⟩
359 View
937 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More